Harmony Biosciences Holdings Inc (HRMY)
$35.59
+0.03
(+0.08%)▲
Performance
- $35.20$35.96$35.59
1.1%
Downside
Day's Volatility :2.11%
Upside
1.03%
- $18.61$39.27$35.59
47.71%
Downside
52 Weeks Volatility :52.6%
Upside
9.36%
Returns
| Period | Harmony Biosciences Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 16.69% | 5.1% | 0.0% |
6 Months | 14.66% | 4.9% | 0.0% |
1 Year | -6.34% | 16.6% | 0.0% |
3 Years | -5.85% | 13.2% | -22.3% |
Highlights
Market Capitalization | 2.0B |
Book Value | $9.48 |
Earnings Per Share (EPS) | 1.95 |
PE Ratio | 18.25 |
Wall Street Target Price | 43.29 |
Profit Margin | 17.53% |
Operating Margin TTM | 12.36% |
Return On Assets TTM | 13.75% |
Return On Equity TTM | 22.47% |
Revenue TTM | 656.1M |
Revenue Per Share TTM | 11.33 |
Quarterly Revenue Growth YOY | 28.799999999999997% |
Gross Profit TTM | 354.4M |
EBITDA | 202.5M |
Diluted Eps TTM | 1.95 |
Quarterly Earnings Growth YOY | -0.64 |
EPS Estimate Current Year | 2.24 |
EPS Estimate Next Year | 3.73 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | 0.65 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 21.64%
Technicals Summary
Sell
Neutral
Buy
Harmony Biosciences Holdings Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Harmony Biosciences Holdings Inc | 6.08% | 14.66% | -6.34% | -5.85% | -3.84% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Harmony Biosciences Holdings Inc | 18.25 | 18.25 | NA | 2.24 | 0.22 | 0.14 | NA | 9.48 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Harmony Biosciences Holdings Inc | Buy | $2.0B | -3.84% | 18.25 | 17.53% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Harmony Biosciences Holdings Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 154.61M → 172.81M (in $), with an average increase of 10.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 38.33M → 11.59M (in $), with an average decrease of 69.8% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 43.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 75.0%
Institutional Holdings
Valor Management LLC
19.74%BlackRock Inc
10.27%FMR Inc
9.22%Vanguard Group Inc
6.19%Vivo Capital, LLC
4.59%State Street Corporation
2.28%
Company Information
patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.
Organization | Harmony Biosciences Holdings Inc |
Employees | 246 |
CEO | Mr. Jeffrey S. Aronin |
Industry | Health Technology |
